Researchers at the Medical University of South Carolina and the University of Florida recently collaborated on a novel, highly specific strategy to treat type 1 diabetes (T1D) using a tagged beta cell transplant in tandem with localized immune protection provided by specialized immune cells also tagged with a complementary but inert targeting molecule.

Positive results from a clinical trial in adults with grade 2 glioma were a Late-Breaking Abstract at the Society of Neuro-Oncology (SNO) 2024 Annual Meeting. The results have an immediate clinical impact, as this is the first evidence from a randomized phase 3 study that temozolomide chemotherapy improves long-term survival for these patients. Radiation therapy plus chemotherapy is the routine initial treatment for patients with this slow-growing form of brain cancer. Some receive PCV chemotherapy based on evidence of benefit from a prior trial. Others receive temozolomide, a chemotherapy pill, because it is less toxic for patients and more manageable for oncologists to administer. However, until E3F05, there was no supporting evidence in grade 2 gliomas that temozolomide was beneficial. The 10-year survival rate was 70% with the combined treatment compared to 47% with radiation alone.